Blanket Purchase Agreement 36F79721D0019-36C25722A0004

Award Date 12/7/21
Last Date to Order 11/14/26
Ultimate Awardee
Veracyte, Inc.
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 8 awarded a $972,177 Blanket Purchase Agreement (BPA) to Veracyte Labs SD Corporation, a division of Decipher Biosciences, Inc., to provide Decipher Prostate Cancer genomic testing services. This single-award IDV contract, utilizing the GSA Medical Laboratory Testing and Analysis Services Schedule, enables VISN 8 facilities to efficiently access Decipher's proprietary molecular diagnostic tests to support...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1 awarded a single-award Blanket Purchase Agreement to Decipher Biosciences, Inc., operating under Veracyte Labs SD Corp, against the Medical Laboratory Testing and Analysis Services schedule. The BPA call provides for prostate testing services in the amount of $390,000 to be performed over an 11-month period in San Diego, California. Specifically, the contractor will deliver Decipher Prostate...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded an indefinite delivery, indefinite quantity contract to Veracyte Labs SD Corp, a division of Decipher Biosciences, Inc., with a potential value of $249,000.00 and a period of performance through September 30, 2023. Against this contract, the agency issued four firm fixed price delivery orders for prostate cancer testing services. The orders called for providing the proprietary...
The key products and services being delivered under this federal contract IDV award are specialized genomic testing services, primarily focused on prostate cancer diagnostics and treatment planning. The prime contractor, Veracyte Labs SD Corporation, a division of Decipher Biosciences, Inc., provides its proprietary Decipher Prostate Cancer Test and other advanced molecular diagnostic capabilities to the Department of Veterans Affairs (VA) and its Veterans Integrated Service Networks (VISNs)...
The federal contract IDV award is for Decipher Prostate Genomic Classifier testing services provided by Veracyte Labs SD Corporation, a division of Veracyte, Inc., to the Department of Veterans Affairs (VA). The single-award Indefinite Delivery Contract has a ceiling value of $194,435.40 and a period of performance through September 30, 2026. Under this IDV, Veracyte will deliver task orders for Decipher Prostate Cancer testing to support the VA's efforts to provide personalized cancer care...
The federal contract IDV award to Veracyte, Inc. under the GSA's Medical Laboratory Testing and Analysis Services Schedule (FSS-621-II) enables multiple federal agencies, including the Department of Veterans Affairs (VA) and Defense Health Agency, to procure Veracyte's genomic testing services. The contract, valued at up to $2.3 million through July 2028, provides access to Veracyte's commercial laboratory capabilities for cancer screening and diagnosis, such as the Afirma Genomic Sequencing...
This indefinite delivery contract was awarded by the Department of Veterans Affairs' Veterans Integrated Service Network (VISN) 23 to Veracyte, Inc., a for-profit medical diagnostics company. The contract, which is not set aside for any specific business category, has a ceiling value of $2,000,000 and an ultimate completion date of April 30, 2028. Under this contract, Veracyte will provide reference laboratory services, including specialized genomic testing and classifier services, to support...
The federal contract IDV award, valued at up to $890,640.00, was issued by the Department of Veterans Affairs' (VA) Veterans Integrated Service Network 16 (VISN 16) to Veracyte, Inc., a for-profit provider of genomic testing services. The single-award IDV, awarded on October 1, 2024 with a potential completion date of September 30, 2029, will enable VISN 16 to efficiently access Veracyte's commercial laboratory capabilities for specialized pathology testing to support VA hospitals and clinics...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a Blanket Purchase Agreement (BPA) to Mdxhealth, Inc., a for-profit healthcare company, for the provision of specialized cancer diagnostic testing services. The BPA is under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule contract (FSS-621-II) and has a total potential value of $280,000 with an ultimate completion date of April 2, 2029. Specifically, the BPA covers DX Prostate Testing,...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a Blanket Purchase Agreement (BPA) to Cytopath Biopsy Lab Inc., doing business as Cblpath, for the provision of ThyroSeq genomic classifier tests. Cblpath is a provider of specialized anatomic pathology and molecular diagnostic laboratory services, and has held multiple federal contracts with the VA and Defense Health Agency to deliver ThyroSeq testing to support cancer screening and diagnosis programs for...

The Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) contract to Veracyte Labs SD Corporation, a division of Veracyte, Inc., for the provision of Decipher Prostate Cancer Testing services. This contract, valued at up to $991,815.95, is established under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II) and does not have a set-aside designation.

The contract aims to support the VA's efforts to provide personalized, precision cancer care to veterans by enabling access to Veracyte's specialized genomic testing capabilities. Veracyte's core product, the Decipher Prostate Cancer Test, is a genomic classifier that analyzes tumor gene expression patterns to help clinicians make more informed treatment decisions for prostate cancer patients. The contract includes several task orders with firm fixed-price values ranging from $3,240.59 to $64,811.80, primarily supporting VA healthcare facilities within the Veterans Integrated Service Network (VISN) 17. Veracyte holds several significant Indefinite Delivery Vehicle (IDV) contracts with the VA and the Department of Defense, allowing these agencies to efficiently procure the company's advanced molecular diagnostic services to support their goals of delivering personalized cancer care to veterans and service members.

Generated 6/10/25, 10:46 AM